Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in HER2-Positive Early Breast Cancer

Drug Information

Target Indication

HER2-Positive Early Breast Cancer

Clinical Trial

Last updated: 1/28/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

RHHBY

Roche Holding AG

Related Pipeline

Obesity

Breast Cancer

Myasthenia Gravis Generalised

Unresectable Hepatocellular Carcinoma

Duchenne Muscular Dystrophy

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts